NCT07639944
An Open Label Study Assessing REN Treatment in Headache Management in Temporomandibular Disorders
Recruiting
NAAges 12+InterventionalTreatmentTheranica
~40 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:Nerivio treatment
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in daily maximum-pain level
Measured over 10 weeks
Conditions
Where it's being run
2 sites across 2 statesMississippi1
New York1
Study leadership
- Alit Stark Inbar, PhD · STUDY_DIRECTOR · Theranica
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in daily maximum-pain level10 weeks
The change in daily maximum-pain level (on the numeric rating scale, NRS, of 0-10) as measured by comparing the average daily maximum orofacial-pain score in the last 2 weeks of baseline phase (weeks 3-4) to the last 2 weeks of the intervention phase (weeks 9-10). Pain score will be taken from any of the orofacial locations specified in the daily diary (jaw, head, neck, ear, eye, face, teeth) that presented the maximum daily pain. Patients will log their maximum pain levels in a daily diary, through a study specific smartphone application.